GENELUX CORPORATION Proceeds from Issuance of Warrants
GENELUX CORPORATION (GNLX) reported Proceeds from Issuance of Warrants of $224.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-03-19
- GENELUX CORPORATION proceeds from issuance of warrants for the quarter ending 2025-12-31 was $210.00K.
- GENELUX CORPORATION proceeds from issuance of warrants for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- GENELUX CORPORATION proceeds from issuance of warrants for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- GENELUX CORPORATION proceeds from issuance of warrants for the quarter ending 2024-06-30 was $0.00.
- GENELUX CORPORATION proceeds from issuance of warrants for fiscal 2025 was $224.00K, a 67.44% decline from fiscal 2024.
- GENELUX CORPORATION proceeds from issuance of warrants for fiscal 2024 was $688.00K, a 76.98% decline from fiscal 2023.
- GENELUX CORPORATION proceeds from issuance of warrants for fiscal 2023 was $2.99M, a 2390.83% increase from fiscal 2022.
- GENELUX CORPORATION proceeds from issuance of warrants for fiscal 2022 was $120.00K.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | $210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $224.00K 10-K · filed 2026-03-19 | ||
| 2025-09-30 | $14.00K 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $688.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $688.00K 10-Q · filed 2025-11-05 | $936.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $688.00K 10-Q · filed 2025-08-07 | $936.00K derived: sum of 3 quarters · filed 2025-08-07 | $2.50M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $688.00K 10-Q · filed 2025-05-06 | $936.00K derived: sum of 2 quarters · filed 2025-05-06 | $2.50M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.81M derived: sum of 2 quarters · filed 2025-03-28 | $2.99M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.74M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $1.17M 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $120.00K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $120.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |